SCHEMBL8035790

SCHEMBL8035790

Cc1noc(-c2nc3ccc(C(=O)N(CCC(C)C)CCC(C)C)cn3c2CCCN(C)C)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 11/20 0.37
SLC2A1 P11166 1/20 0.35
TBXAS1 P24557 2/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
ALB P02768 1/20 0.32
CYP3A4 P08684 1/20 0.32
CHRM1 P11229 1/20 0.32
GABRA1 P14867 1/20 0.32
HPGD P15428 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA3 P34903 1/20 0.32
ADRA1A P35348 1/20 0.32
OPRK1 P41145 1/20 0.32
HTR2B P41595 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRB2 P47870 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11929582 0.82 MC4R (0.39) MC4RSLC2A1TBXAS1KDM4ELMNA
SCHEMBL8037985 0.81 MC4R (0.41) MC4RSLC2A1TBXAS1
SCHEMBL8046080 0.79 MC4R (0.39) MC4RSLC2A1TBXAS1
SCHEMBL8046141 0.78 MC4R (0.39) MC4RTBXAS1
SCHEMBL11929572 0.77 SLC2A1 (0.37) MC4RSLC2A1TBXAS1ALBOPRK1
SCHEMBL8034742 0.77 MC4R (0.37) MC4RSLC2A1
SCHEMBL14046548 0.74 SLC2A1 (0.42) MC4RSLC2A1KDM4ELMNAALB
SCHEMBL11929573 0.73 MC4R (0.42) MC4R
SCHEMBL4671674 0.72 SLC2A1 (0.41) MC4RSLC2A1KDM4ELMNAALB
SCHEMBL11929574 0.71 MC4R (0.47) MC4RSLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324036-A1 SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2010-12-23 US disclosed
WO-2009080291-A1 SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324036-A1 SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS MC4R, MC5R, MC3R MC4R 1/4885SLC2A1 4133/4885TBXAS1 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.